OCC Targeted Therapy & Immunotherapy in Oncology 3

Question 1

Moderate to severe immune-related adverse events (irAEs) from checkpoint inhibitors are primarily managed with:

Accepted Answer

Holding the checkpoint inhibitor and initiating systemic corticosteroids

Answer

Moderate to severe irAEs require holding the checkpoint inhibitor and initiating high-dose systemic corticosteroids (e.g., prednisone 1-2 mg/kg/day) to suppress aberrant immune activation.

Question 2

A patient on cetuximab (EGFR inhibitor) develops a papulopustular acneiform rash. This finding most likely indicates:

Accepted Answer

A pharmacodynamic marker associated with tumor response and survival benefit

Answer

The acneiform/papulopustular rash from EGFR inhibitors is a recognized pharmacodynamic marker correlating with drug activity and is associated with improved tumor response and overall survival.

Question 3

Hand-foot skin reaction (HFSR) with painful, thickened skin on palms and soles is a characteristic toxicity of which class?

Accepted Answer

Multikinase inhibitors targeting VEGFR (sorafenib, sunitinib)

Answer

HFSR is a class effect of VEGFR-targeting multikinase inhibitors (sorafenib, sunitinib, regorafenib, cabozantinib) due to disruption of skin repair mechanisms.

Question 4

Grade 3-4 immune-related colitis that does not respond to high-dose corticosteroids should be treated with:

Accepted Answer

Infliximab (anti-TNF monoclonal antibody)

Answer

Infliximab, an anti-TNF antibody, is the recommended treatment for steroid-refractory immune-related colitis as it effectively suppresses TNF-mediated intestinal inflammation.

Question 5

A patient receiving CAR-T cell therapy develops fever (39.5°C), hypotension, and hypoxia 18 hours post-infusion. First-line treatment for this severe cytokine release syndrome (CRS) is:

Accepted Answer

Tocilizumab (anti-IL-6 receptor antibody)

Answer

Tocilizumab, an anti-IL-6 receptor antibody, is the first-line treatment for severe CRS (grade ≥3) from CAR-T therapy, as IL-6 is the primary cytokine driving this syndrome.

(OCC) Oncology Chemotherapy Certification Practice Test

(OCC) Oncology Chemotherapy Certification Practice Test

OCC Targeted Therapy & Immunotherapy in Oncology 3